Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

Injectable GLP-1 drugs have become game-changers for treating obesity and Type 2 diabetes. Now, a GLP-1 in pill form continues to show promising results for weight loss and blood sugar ... which means ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Mounjaro weight loss jabs now available from GPs – are you eligible? - Around 29% of the adult population in the UK is obese ...

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

Mounjaro has been approved for both type 2 diabetes and weight loss, but access will be limited by strict eligibility criteria ...

Weight loss injections are now available on the NHS but experts warn thousands of patients may be vulnerable to serious side ...

Since the GLP-1 drugs, including Mounjaro, Ozempic and Wegovy, were licensed, there have been hundreds of reported cases of ...

Both Wegovy and Ozempic are semaglutide – a drug that first entered the US market in 2017 as a diabetes medication. It was ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...